. .

 
Zuruecksetzen

Suchergebnis - MERCK CO. DL-01 REGISTERED SHARES DL-,01

Zeit Titel
25.09 13:17dpa-AFX: Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival
25.09 12:57dpa-AFX: *MERCK SAYS PHASE 3 KEYFORM-007 TRIAL FAILS TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL
25.09 12:56dpa-AFX: Merck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLC
25.09 12:46dpa-AFX: *MERCK'S KEYTRUDA GETS NEW APPROVALS IN JAPAN FOR PATIENTS WITH NSCLC AND RADICALLY UNRESECTABLE UROTHELIAL CARCINOMA
24.09 16:16dpa-AFX: Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus
18.09 13:52dpa-AFX: Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
18.09 13:20dpa-AFX: *MERCK: FDA APPROVES KEYTRUDA PLUS PEMETREXED AND PLATINUM CHEMOTHERAPY FOR ADULT PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
18.09 11:44dpa-AFX: Merck & Co To Present At Bank Of America Global Healthcare Conference; Webcast At 6:40 AM ET
17.09 18:21MÄRKTE USA/Börsen mit leichten Aufschlägen
17.09 12:45dpa-AFX: Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
17.09 12:08dpa-AFX: *DAIICHI SANKYO AND MERCK: HERTHENA-LUNG02 PHASE 3 TRIAL OF PATRITUMAB MEETS PRIMARY ENDPOINT
15.09 18:54dpa-AFX: Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial
12.09 13:35dpa-AFX: Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours
12.09 13:03dpa-AFX: *HEALTH CANADA APPROVES KEYTRUDA AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC MSI-H OR DMMR SOLID TUMOURS
09.09 22:10MÄRKTE USA/Rücksetzer folgt teilweise Erholung - Apple-Präsentation bewegt kaum
09.09 18:18MÄRKTE USA/Aktien nach Rücksetzer auf Wiedergutmachungskurs
09.09 15:54MÄRKTE USA/Wall Street mit leichter Erholung
09.09 15:31dpa-AFX: *MERCK & CO -4% - POSITIVE STUDIE ZU POTENZIELLEM KONKURRENZPRODUKT ZU KEYTRUDA
09.09 14:56MÄRKTE USA/Wall Street vor leichter Erholung
09.09 12:57dpa-AFX: *MERCK & CO -4% VORB. - POSITIVE STUDIENDATEN ZU POTENZIELLER KEYTRUDA-KONKURRENZ

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH